a b s t r a c t AZD3965, a pyrole pyrimidine derivative, is a potent and orally bioavailable inhibitor of monocarboxylate transporter 1 (MCT1), currently in a Phase I clinical trial in UK for lymphomas and solid tumors. There is currently no published assay for AZD3965. The objectives of this study were to develop and validate a LC/MS/MS assay for quantifying AZD3965 in mouse plasma and tumor tissue. Protein precipitation with 0.1% formic acid in acetonitrile was used for sample preparation. Chromatographic separation was achieved on a C18 column followed by tandem mass spectrometry detection in multiple reaction monitoring mode with utilizing Atmospheric Pressure Chemical Ionization. AR-C155858 was used as the internal standard. The inter-day and intra-day precision and accuracy of quality control samples evaluated in plasma and tumor tissue were less than ±7% of the nominal concentrations. The extraction recovery, matrix effect and stability values were all within acceptable levels. Sample dilution integrity, accessed by diluting plasma spiked with AZD3965 10-fold with blank plasma, was 101%. The lower limit of quantification (LLOQ) and upper limit of quantification (ULOQ) were 0.15 ng/mL and 12 g/mL, respectively, in plasma. The assay of AZD3965 in tumor tissue was also validated with good precision and accuracy. The LLOQ was 0.15 ng/mL in tumor tissue. This assay was successfully applied to pharmacokinetic and murine 4T1 breast tumor xenograft studies of AZD3965 in mice.
Introduction
AZD3965, a pyrole pyrimidine derivative and an analogue of AR-C155858, represents a first-in-class monocarboxylate transporter 1 (MCT1) inhibitor that is currently being investigated in a Phase I clinical trial in the UK for solid tumors and lymphoma treatment (NCT01791595) (Scheme 1A). Targeting lactate transporters (MCTs) as potential therapeutic targets in cancer has been proposed in recent years, due to the increasing reports of MCT1 and/or MCT4 up-regulation in various cancers [1] [2] [3] . MCT inhibition or silencing RNA have shown to limited the survival of cancer cells and decreased tumor growth in various preclinical tumor models [4] [5] [6] [7] .
In this study, we developed and validated a LC/MS/MS method for quantifying AZD3965 in mouse plasma and breast tumor tissue using AR-C155858 (Scheme 1B) as the internal standard. The method is able to quantitate AZD3965 in mouse plasma and tumor tissue selectively and accurately over a wide range of concentrations. Our results demonstrate the applicability of our assay in pharmacokinetic and murine 4T1 breast tumor xenograft studies in mice following the oral and intraperitoneal administration of 100 mg/kg AZD3965, respectively.
Materials and methods

Chemicals and reagents
AZD3965 (>98% purity) and AR-C155858 (≥98% purity) were purchased from MedKoo Biosciences (Chapel Hill, NC) and Chemscene (Monmouth Junction, NJ), respectively. All other reagents used were HPLC grade and were purchased from Sigma-Aldrich (St. Louis, MO). 
Cell culture
Mouse mammary tumor, 4T1 cells were kindly provided by Dr. Elizabeth A. Repasky (Roswell Park Cancer Institute, Buffalo NY). Cells were maintained at 37 • C in a humidified atmosphere with 5% CO 2 /95% air. 4T1 cells were cultured in Roswell Park Memorial Institute 1640 medium supplemented with 10% fetal bovine serum (FBS), 100 units penicillin and 100 g/mL of streptomycin. Culture medium was changed every 2-3 days, and cells were passaged with 0.25% Trypsin/EDTA.
LC/MS/MS and chromatographic conditions
The LC/MS/MS assay was performed on Shimadzu Prominence HPLC with binary pump and autosampler (Shimadzu Scientific, Marlborough, MA) connected to a Sciex API 3000 triple quadruple tandem mass spectrometer with Atmospheric Pressure Chemical Ionization (APCI) (Sciex, Foster City, CA). Chromatographic separation was achieved by injecting 15 or 4 L of the sample on to an Xterra MS C18 column (250 × 2.1 mm i.d., 5-m particle size; Waters, Milford, MA) for the low or high calibration curve, respectively. Mobile phase A consisted of acetonitrile/water (5/95, v/v) with 0.1% acetic acid. Mobile phase B was acetonitrile/water (95/5, v/v) with 0.1% acetic acid. The flow rate was 250 L/min with a gradient elution profile and a total run time of 15 min. The mass spectrometer was operated in multiple reaction monitoring (MRM) mode utilizing APCI for specific detection of AZD3965 and the I.S. by measuring the characteristic ion transition. The mass spectrometer parameters were optimized: declustering potential of 35 V, entrance potential of 10 V, and collision cell exit potential of 25 V. The nebulizer current was 3 uA with the source temperature at 450 • C. The selected mobile phase, column, chromatographic conditions and sample preparation were modified from our preliminary validated assay for AR-C155858 (an analogue of AZD3965) in rat plasma [8] . The data was analyzed using Analyst version 1.4.2 (Sciex, Foster City, CA).
Standard and quality control solutions
AZD3965 and the I.S., AR-C155858 were dissolved in DMSO at a concentration of 1 mg/mL. Separate stock solutions for calibration standards and quality control (QC) samples were then diluted in acetonitrile/water (40/60, v/v). These stock solutions were further diluted in acetonitrile/water (20/80, v/v) to obtain working solutions. All the stock and working solutions were stored at −20 • C. The concentrations of the calibration standard samples were 0.15, 0.5, 5, 20, 50, 100, 250, and 500 ng/mL for the low calibration curve and 100, 200, 500, 1000, 2500, 5000, 8000, and 12000 ng/mL for the high calibration curve. Low-, medium-and high-QC samples were prepared to yield concentration of 10, 150, and 400 ng/mL for the low calibration curve and 1000, 6000, and 10000 ng/mL for the high calibration curve. The I.S. concentrations were 15 and 200 ng/mL for the low and high calibration standard and QC samples, respectively.
Sample preparation
For tumor samples, tumors were thawed on ice and homogenized in methanol/water (5/95 v/v) (5 mL/g tumor). Samples were prepared by adding 5 L of I.S. solution containing AR-C155858 to 35 L of the plasma or tumor homogenate sample. To ensure the concentrations quantified were below the upper limit of quantification (ULOQ), part of the plasma samples were diluted 10-fold with blank plasma prior to the sample preparation. Standards and QCs were prepared by adding 5 L of I.S. solution and 5 L of stock solution containing AZD3965 to 30 L of blank plasma or blank tumor homogenate. Plasma and tumor homogenate proteins were precipitated by the addition of 600 L 0.1% formic acid in acetonitrile. Samples were vortexed, followed by centrifugation at 10,000×g for 20 min at 4 • C. Then 540 L of the supernatant was collected and evaporated under a stream of nitrogen gas, followed by reconstitution in 200 and 1000 L of acetonitrile/water (40/60, v/v) for low and high calibration curve, respectively.
Assay validation 2.6.1. Linearity and lower limit of quantification
Regression analysis of peak area ratios of AZD3965/AR-C155858 to AZD3965 concentrations was used to assess linearity of the curve. The linearity of the calibration curves was determined utilizing 1/ weighting factor ( = concentration). The guideline used to determine the lower limit of quantification (LLOQ) and detection (LOD) was based on a signal-to-noise ratio (S/N) of at least 10:1 and 3:1, respectively.
Precision and accuracy
The intraday precision and accuracy were determined by analyzing QC samples in triplicate on each day. Whereas for the interday precision and accuracy, QC samples were analyzed over three different days. A calibration curve was run on each analysis day along with the QCs. The precision was determined by the coefficient of variation, and accuracy was measured by comparing the calculated concentration with the known concentration. The acceptable precision and accuracy were required to be within ±15%.
Recovery and matrix effect
The recoveries of the AZD3965 and I.S. were determined by comparing the peak areas of extracted standard samples with the peak areas of post-extraction plasma spiked at the corresponding QC concentrations (low, middle and high). The matrix effect was evaluated by comparing the peak areas of post-extraction plasma and tumor homogenate spiked with QC (low and high) to the neat QC solutions. For post-extraction spiked plasma and tumor homogenate samples, 40 uL of blank plasma or tumor homogenate were precipitated with 0.1% formic acid in acetonitrile and centrifuged as described in Section 2.5. The resulting supernatant (540 L) was dried and reconstituted in 190 and 990 L of acetonitrile/water (40/60, v/v) for low and high calibration curve, respectively plus 5 uL of I.S solution and 5 uL of QC stock solution. The neat QC solutions were prepared similarly as the post-extraction spiked plasma and tumor homogenate samples but in the absence of matrix. Both recovery and matrix effect were examined in triplicate.
Effect of dilution
The effect of dilution was evaluated for the analysis of AZD3965 in plasma at concentrations higher than the ULOQ by analyzing duplicates of plasma spiked with AZD3965 at 10-fold dilution of the three QC concentrations (10,000, 60,000 and 100,000 ng/mL) and diluting with blank plasma to the corresponding QC concentrations for the high calibration curve.
Stability
The post preparative stability was determined by rerunning QC samples that were kept in the autosampler at 15 • C for at least 16 h. The stability of AZD3965 in mouse plasma and tumor tissue were assessed after three freeze-thaw cycles (−80 • C to room temperature) by analyzing QCs samples in triplicate. For long-term stability evaluations, QC samples in mouse plasma (low, medium and high concentrations of the low calibration curve), obtained from the same aliquots that were used to assess interday variability, were evaluated in duplicate after storage for 15 months in −80 • C.
Application in pharmacokinetic and breast tumor xenograft studies
Female, BALB/c mice weighting 18-20 g were purchased from Envigo (Indianapolis, IN). Animals were housed in a filtered laminar airflow room in standard vinyl cages with air filter tops. Water and food were autoclaved and provided ad libitum. Animals were maintained under the standard 12-h light/dark cycle at 22-24 • C. All animal procedures were approved by the Institutional Animal Care and Use Committee at the University at Buffalo.
For the pharmacokinetic study, mice were administered an oral dose of 100 mg/kg AZD3965 by oral gavage. AZD3965 stock solution (10 mg/mL) was prepared in 20% w/v cyclodextrin in normal saline. Three mice per time-point were sacrificed after 15 and 30 min, and 1, 2, 3, 6, 9, 12, and 24 h by aortic exsanguination. Blood samples were collected and centrifuged within 1 h for plasma extraction. All the samples were stored at −80 • C until analysis.
For the tumor study, mice were lightly anesthetized and injected with 100 uL of cell suspension subcutaneously into the 4th inguinal mammary fat pad at a cell density of 2.5 × 10 5 cells/mL in 1 × PBS. Prior to inoculation, 4T1 cells were treated with trypsin, washed and resuspended in 1 × PBS. When the tumor volume reached 100 mm 3 , three animals were given AZD3965 intraperitoneally (i.p.) twice daily for 17 days. Twelve hours after the last AZD3965 dose, the primary tumor was excised and snapped frozen in liquid nitrogen. Terminal blood samples were collected in a lithiumheparinized tube. Blood samples were centrifuged and plasma was extracted. All the samples were stored at −80 • C until analysis.
Data and statistical analysis
Noncompartmental analysis was performed using Phoenix WinNonlin version 7.0 (Pharsight, Mountain View, CA) to determine AZD3965 pharmacokinetic parameters. Area under the plasma concentration-time curve (AUC) was determined using the trapezoidal method; with AUC values extrapolated to time infinity. The terminal half-life (t 1/2 ) was calculated as 0.693/k, where k is the slope of the terminal regression line. V z /F (apparent volume of distribution/bioavailability (F)) represents the apparent volume of distribution estimated from the terminal phase. The maximal concentration (C max ) was also determined by visual inspection. Oral clearance (clearance/F) was determined by the oral dose/AUC. All the data are presented as mean ± SD. Data analysis was performed using GraphPad Prism (GraphPad Software Inc., San Diego CA). Student's t-test was used to assess the statistical significance with p value <0.05.
Results
The assay presented here has been validated according to the US Food and Drug Administration (FDA) guidelines: Bioanalytical 
LC/MS/MS and chromatograms
Our AZD3965 method was optimized to obtain good peak shapes, chromatographic separation and reproducibility. The Q1 (first quadruple) full scan and product ion scan mass spectra of AZD3965 are presented in Fig. 1A and B, respectively. Q1/Q3 m/z ratio for the precursor/product ion of AZD3965 and AR-C15585 (I.S.) was 516.4/413.2 and 462.3/373.2, respectively. The representative chromatograms of mouse plasma and tumor tissue homogenate spiked with AZD3965 and I.S. are shown in Fig. 2A and B, respectively. The retention times of AZD3965 and AR-C155858 (I.S.) were 5.77 and 4.91 min, respectively. Additional system suitability parameters such as tailing factor and theoretical plates were also evaluated and the results are summarized in Table 1 . No peaks were observed in the blank mouse plasma and tumor tissue samples at the retention time of AZD3965 and I.S. (Fig. 2C and D) , indicating no matrix interference is present.
Validation of the assay
Linearity and lower limit of quantification
The calibration curves were linear over the AZD3965 concentration range of 0.15-500 ng/mL in both plasma and tumor tissue. The high concentration calibration curves were also linear over the AZD3965 concentration range of 100-12000 ng/mL in plasma. The correlation coefficients (r 2 values) were all greater than 0.999. Using our assay, the LLOQ and ULOQ for AZD3965 was found to be 0.15 and 12000 ng/mL, respectively in plasma. The LLOQ in tumor tissue was found to be 0.15 ng/mL.
Precision and accuracy
Intra-day and inter-day precision and accuracy were evaluated by analyzing QC samples (low, medium and high concentration) in both plasma and tumor tissue matrix in triplicate. The results of the assay performance are summarized in Tables 2 and 3 . The intra-day and inter-day CV% for precision and accuracy of the assay were less than ±7% of the nominal concentrations.
Effect of dilution
A total of six replicates of plasma spiked with AZD3965 (duplicate of each of high calibration QC concentrations) were diluted 10-fold with blank plasma were evaluated for sample dilution integrity. The average accuracy and CV% from the plasma dilution were 101% and 5.37%, respectively.
Recovery and matrix effect
The recovery of AZD3965 in plasma is shown in Table 2 and the overall mean extraction was 102%. The matrix effects of AZD3965 in both matrices are summarized in Tables 2 and 3 and the results indicate no matrix effect in mouse plasma and tumor tissue.
Stability
Our stability studies demonstrated AZD3965 was stable under different storage conditions. The concentrations of AZD3965 from Table 2 AZD3965 recovery, matrix effect, intra-day and inter-day accuracy and precision in mouse plasma. The measured concentrations represent the mean of triplicate measurements. The analyses were performed over 3 days.
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1.68 95.7 105 97.8 1.41 Table 3 AZD3965 matrix effect, intra-day and inter-day accuracy and precision in the murine 4T1 breast tumor tissue. The measured concentrations represent the mean of triplicate measurements. The analyses were performed over 3 days.
Nominal concentration (ng/mL) the stability analysis in mouse plasma (long term, three freezethaw cycles and post-preparation) were all less than ±15% of the nominal values. The stock solutions were demonstrated to be stable in −20 • C for a least 12 months with standard deviations less than 10% of the mean.
Application in a PK and breast tumor xenograft studies
The applicability of the validated assay was demonstrated by analyzing plasma samples obtained in a preliminary pharmacokinetic study in mice. The pharmacokinetic parameters of AZD3965 after oral administration demonstrated a half-life of 4.45 h, maximal plasma concentration of 58.8 nmol/mL, time of maximal concentration of 0.333 h, oral clearance (clearance/bioavailability (CL/F)) of 1.40 L/h/kg, and apparent volume of distribution (V/F) of 9.00 L/kg. The AZD3965 concentration time profile in plasma following an oral dose of 100 mg/kg is presented in Fig. 3A . The applicability of the validated assay was also applied to assess total tumor AZD3965 concentrations in a preliminary murine 4T1 breast tumor xenograft study. Plasma and total tumor AZD3965 concentrations measured 12 h after the last AZD3965 dose (100 mg/kg twice daily for 17 days) are presented in Fig. 3B. 
Discussion
Studies have demonstrated potency and efficacy of AZD3965 in tumor xenograft models such as those of human small cell lung cancer and various types of lymphoma and breast cancer [9] [10] [11] [12] [13] [14] . AZD3965, a first-in-class monocarboxylate transporter 1 (MCT1) inhibitor is being evaluated in a Phase I clinical trial in the UK for solid tumors and lymphoma treatment (NCT01791595). However, the PK of AZD3965 and the concentration-effect relationships of AZD3965 have not been previously investigated. Although free plasma AZD3965 concentrations in a Raji lymphoma tumor xenograft model have been reported by Curtis et al. [15] , there is no report of an analytical method developed and validated for quantification of AZD3965 concentration in biological fluids. Therefore, in our current study, we developed and validated an LC/MS/MS assay for use in preclinical animal studies. Previously, our laboratory has reported a preliminary validated LC/MS/MS assay for AR-C155858 (an analogue of AZD3965) in rat plasma [8] . With the incorporation of AR-C155858 as an internal standard, our current LC/MS/MS assay was successfully validated in mouse plasma and 4T1 breast tumor tissue over a wide range of AZD3965 concentrations with high selectivity and good precision and accuracy.
From our preliminary PK study, the mean maximum plasma concentration occurred around 0.33 h, indicating the oral absorption of AZD3965 is relatively fast. This short t max observed in our study was in good agreement with previously reported results [15] . The mice used in our PK study were not fasted, and we observed a small reentry peak in plasma of AZD3965 between 6 and 9 h, which might suggest the enterohepatic recycling of AZD3965. The apparent volume of distribution was 9.07 L/kg indicating extensive tissue distribution and binding is likely. Further AZD3965 PK studies are needed to confirm our findings. In our murine 4T1 breast tumor xenograft study, the total tumor AZD3965 concentration was found Fig. 3 . Plasma concentration of AZD3965 after oral administration of 100 mg/kg of AZD3965 in female Balb/c mice (A). Plasma and total tumor AZD3965 concentration measured 12 h after the last AZD3965 dose (100 mg/kg, i.p) in the murine 4T1 breast tumor xenograft (B). Assuming tumor density of 1 g/cm 3 , tumor AZD3965 concentrations were normalized per gram of tumor tissue and expressed as nM. ** P < 0.01, compared to the plasma AZD3965 concentration (nonparametric Student's t-test). All the data are presented as mean ± SD, n = 3.
to be significantly higher (25.5-fold higher) than that in the plasma, suggesting extensive tumor uptake and accumulation of AZD3965.
Conclusion
The LC/MS/MS assay described in our current study shows high selectivity, precision and accuracy for the determination of AZD3965 in mouse plasma and tumor tissue over a wide range of concentrations. The assay was validated according to the FDA guidelines on analytical procedure and method validation. Our assay was successfully applied for the analysis of plasma samples in preliminary pharmacokinetic and breast tumor xenograft studies of oral AZD3965 in mice.
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